Motif Bio Plc (NASDAQ: MTFB) is having an incredibly rough start to the trading session this morning, and for good reason. The company received a CRL, or Complete Response Letter, from the FDA. This letter outlined a rejection of a New Drug Application, upsetting investors and sending the stock tumbling. Today, we’ll talk about: The … Read more
Durect Corp. (NASDAQ:DRRX) On Monday, Durect Corp stock fell by 32% after Pain Therapeutics (PTIE) received a Complete Response Letter — CRL — from the Food and Drug Administration — FDA. The drug that received the CRL is known as Remoxy ER, and was Pain’s drug obtained through a license from Durect Corp. The FDA … Read more
Relypsa Inc. (NASDAQ: RLYP) On July 21, 2016 shares of Relypsa soared higher by 58% after it was announced that Swedish drug maker Galencia purchased the company. Galencia had bought Relypsa in an all cash deal for $32 per share or $1.53 billion. There are two reasons why Galencia had paid so much to acquire … Read more